FDA approves minimally-invasive, non-drug therapy for pain management
from Monthly Prescribing Reference
SPR Therapeutics announced that the U.S. Food and Drug Administration has granted clearance for SPRINT endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation (PNS) Systems. The percutaneous SPRINT PNS System is indicated for use up to 60 days in the back and/or extremities for chronic and acute pain, including post-operative and post-traumatic pain. The System leads are placed by a physician during an outpatient procedure; no surgery, incisions, tissue destruction or anesthesia are required.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063